Barclays on Rapt Therapeutics (RAPT): 'RPT904 shows numerically better UAS7 improvements compared to Xolair at every time point'
Tweet Send to a Friend
Barclays analyst Etzer Darout reiterated an Overweight rating and $35.00 price target on Rapt Therapeutics (NASDAQ: RAPT).The analyst comments "RPT904 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
